LONDON - UK biotech needs to find a new way of funding start-ups. Even before the current financial crisis, institutional investors had lost interest in the sector because returns are too long term and too uncertain. (BioWorld International) Read More
No Abstract BioWorld International CorrespondentPARIS - DBV Technologies, which specializes in the diagnosis and treatment of allergies, completed a series B financing in which it raised €6 million (US$7.9 million) from one new and one existing investor. Read More
